Anlotinib in Metastatic HER2 Negative Breast Cancer

Status:
Completed

Trial end date:
2020-03-15

Target enrollment:

Participant gender:

The hypothesis of this study is to discover if the anlotinib can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.

Phase 2

Peng Yuan